Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-01

Clinical Trial Update: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating selexipag for pulmonary arterial hypertension has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Selexipag (Uptravi) (Selexipag)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2016-03-01